<DOC>
	<DOCNO>NCT00094653</DOCNO>
	<brief_summary>The purpose study determine safety efficacy MDX-010 ( ipilimumab , BMS-734016 ) ( anti-CTLA4 ) combination MDX-1379 ( gp100 , BMS-734019 ) patient previously treat , unresectable Stage III IV melanoma . Survival time evaluate , well patient response time disease progression . Eligible patient response single regimen contain interleukin-2 ( IL-2 ) , dacarbazine , and/or temozolomide , 1 ) relapse follow objective response ( partial response/complete response [ PR/CR ] ) ; 2 ) fail demonstrate objective response ( PR/CR ) ; 3 ) could tolerate regimen due unacceptable toxicity . Patients randomize one three group , receive one follow treatment : MDX-010 alone , MDX-1379 alone , MDX-010 combination MDX-1379 .</brief_summary>
	<brief_title>MDX-010 Antibody , MDX-1379 Melanoma Vaccine , MDX-010/MDX-1379 Combination Treatment Patients With Unresectable Metastatic Melanoma</brief_title>
	<detailed_description>Melanoma account approximately 5 % skin cancer United States , account 75 % skin cancer death . In 2004 , expect prevalence melanoma 627,252 , 119,178 case Stage III IV ( metastatic melanoma ) . First line treatment metastatic melanoma , usually IL-2 , dacarbazine and/or temozolomide , associate significant toxicity . MDX-010 ( anti-CTLA4 ) antibody design keep immune system run block CTLA-4 down-regulating T cell activation . MDX-1379 make two peptide piece big melanoma protein ( gp100 ) . These peptide bind HLA-A2 recognize T cell .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosed malignant melanoma Measurable unresectable Stage III IV melanoma HLAA*0201 positive Previous treatment &amp; failure/relapse/inability tolerate IL2 , dacarbazine and/or temozolomide At least 4 week since prior treatment Negative pregnancy Life expectancy great 4 month Eastern Cooperative Oncology Group ( ECOG ) performance 0 1 Required lab value Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) negative Prior malignancy patient disease free 5 year , except treat cure basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix , cancer Ocular melanoma Active , untreated central nervous system ( CNS ) metastasis Prior treatment MDX010 ( antiCTLA4 ) antibody Prior treatment cancer therapeutic vaccine Active autoimmune disease history autoimmune disease Pregnancy nursing Hypersensitivity Incomplete Freund 's Adjuvant ( IFA ) ( Montanide ISA51 ) Underlying medical condition deem hazardous treat study drug Concomitant therapy antimelanoma drug , chemotherapy , investigational therapy , chronic use systemic corticosteroid Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>melanoma</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>skin cancer</keyword>
</DOC>